About: Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.55 (+3.81%)
NYR ASX Nyrada Inc
Nyrada Inc share price
NYR price activity
Último preço
$ 0,550
Variação (24h)
0,02 AUD (3,81%)
Volume
111.07K
Volume (média 4 sem.)
-
Abertura
$ 0,53
Variação do dia
$ 0,53 - $ 0,55
Fechamento anterior
$ 0,53
Último negócio
06 Oct, 5:10 am GMT+0
Atrasado
06 Oct, 5:10 am GMT+0
NYR price performance
Atrasado
06 Oct, 5:10 am GMT+0
quote.marketSignals